Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers
Weitao Fu,Minkui Zhang,Jianing Liao,Qing Tang,Yixuan Lei,Zhou Gong,Luhu Shan,Mojie Duan,Xin Chai,Jinping Pang,Chun Tang,Xuwen Wang,Xiaohong Xu,Dan Li,Rong Sheng,Tingjun Hou
DOI: https://doi.org/10.1021/acs.jmedchem.1c01287
IF: 8.039
2021-01-01
Journal of Medicinal Chemistry
Abstract:Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist 92 targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), 92 demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (26, IC50 = 5.57 mu M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, 92 was discovered with 32.7-fold improved AR antagonistic activity (IC50 = 0.17 mu M). Besides showing high bioactivity and safety, 92 can inhibit AR nuclear translocation. Furthermore, 92 inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.